Fungal CNS infections in patients with hematologic malignancy

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 5, 2005, Pages 775-785

  Pagano, Livio ^a   Caira, Morena ^a   Falcucci, Paolo ^a   Fianchi, Luana ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aspergillus; Candida; Cryptococcus; Zygomycetes

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; DEOXYCHOLIC ACID; ECHINOCANDIN; FLUCYTOSINE; GALACTOMANNAN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE; VORICONAZOLE;

ABSCESS DRAINAGE; ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; AUTOPSY; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BRAIN ABSCESS; BRAIN VENTRICLE PERITONEUM SHUNT; CANDIDIASIS; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID DRAINAGE; CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCOSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; FUNGAL MENINGITIS; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENCE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFECTION RISK; INTERMETHOD COMPARISON; INTRACRANIAL HYPERTENSION; LATEX AGGLUTINATION TEST; LOW DRUG DOSE; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENTERAL NUTRITION; PHAEOHYPHOMYCOSIS; POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; STEREOTAXIS; STEROID THERAPY; SURGICAL INFECTION; SYMPTOMATOLOGY; TRICHOSPORON; ZYGOMYCETES;

ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS;

EID: 27544438094     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.5.775     Document Type: Review

References (107)

1. Denning DW. Invasive aspergillosis. Clin. Infect. Dis. 26, 781-805 (1998).
2. Manuel RJ, Kibbler CC. The epidemiology and prevention of invasive aspergillosis. J. Hosp. Infect. 39, 95-106 (1998).
3. Patterson TF, Kirkpatrick WR, White M et al. for the I3 Aspergillus Study Group. Invasive aspergillosis. Disease spectrum, treatment, practices and outcomes. Medicine 79, 250-260 (2000).
4. Pagano L, Girmenia C, Mele L et al. for GIMEMA Infection Program. Infections caused by filamentous fungi in patients with hematological malignancies. A report of 391 cases by GIMEMA infection. Haematologica 86, 862-870 (2001).
5. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358-4366 (2002).
6. Subirà M, Martino R, Franquet T et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 87, 528-534 (2002).
7. Gerson SL, Talbot GH, Hurwitz S et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann. Intern. Med. 100(3), 345-351 (1984).
8. Ng TT, Robson GD, Denning DW, Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140(Pt 9), 2475-2479 (1994).
9. Dubey A, Patwardhan RV, Sampth S, Samosh V, Kolluri S, Nanda A. Intracranial fungal granuloma: analysis of 40 patients and review of the literature. Surg. Neurol. 63(3), 254-260 (2005).
10. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol. Int. 53, 744-750 (2003).
11. Kami M, Machida U, Okuzumi K et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br. J. Haematol. 117, 40-46 (2002).
12. Hori A, Kami M, Kishi Y, Machida U, Matsumura T, Kashima T. Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J. Hosp. Infect. 50(3), 175-182 (2002).
13. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32, 358-366 (2001).
14. Baddley JW, Salzman D, Pappas PG. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic, and clinical features. Clin. Transplant. 16(6), 419-424 (2002).
15. Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. Am. J. Roentgenol. 162(1), 155-159 (1994).
16. Yamada K, Shrier DA, Rubio A et al. Imaging findings in intracranial aspergillosis. Acad. Radiol. 9(2), 163-171 (2002).
17. Wilson BG. CT assessment of CNS complications of AIDS. Radiol. Technol. 73(5), 424-437 (2002).
18. Innocenti R, Degl'Innocenti L, Fronzaroli C, Ferrante F, Corradi F. Radiologic miliary patterns of cerebral tuberculosis. Arch. Neurol. 62(1), 153-154 (2005).
19. Carradice D, Szer J. Cerebral nocardiosis after allogeneic bone marrow transplantation. Intern. Med. J. 34(12), 698-699 (2004).
20. Kami M, Shirouzu I, Mitani K et al. Early diagnosis of central nervous system aspergillosis with combination use of cerebral diffusion-weighted echo-planar magnetic resonance image and polymerase chain reaction of cerebrospinal fluid. Intern. Med. 38(1), 45-48 (1999).
21. Viscoli C, Machetti M, Gazzola P et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J. Clin. Microbiol. 40(4), 1496-1499 (2002).
22. Groll ALL, Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182(1), 274-282 (2000).
23. Barrett JP, Vardulaki KA, Conlon C et al. Amphotericin B Systematic Review Study Group. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther. 25(5), 1295-1320 (2003).
24. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin. Ther. 25 (5), 1321-1381 (2003).
25. Vermes A, van Der Sijjs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 46, 86-94 (2000).
26. Naim-Url-Rahman, Troke PF, Schwartz S et al. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. Interscience Conference on Antimicrobial Agents and Chemotherapy (2003).
27. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12(6), 1147-1201 (1990).
28. Siddiqui AA, Shah AA, Bashir SH. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: clinical spectrum and outcome in 25 cases. Neurosurgery 55(3), 602-611 (2004).
29. Pagano L, Ricci P, Tonso A et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto) Br. J. Haematol. 99(2), 331-336 (1997).
30. Jantunen E, Volin L, Salonen O et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 31(3), 191-196 (2003).
31. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21, 240-248 (2002).
32. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34(5), 563-571 (2002).
33. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36(9), 1122-1131 (2003).
34. Troke PF, Schwartz S, Ruhnke M et al. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (2003).
35. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37, S188-S224 (2003).
36. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob. Agents Chemother. 48(3), 693-715 (2004).
37. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39(6), 797-802 (2004).
38. Damaj G, Ivanov V, Le Brigand B et al. Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Ann. Hematol. 83(6), 390-393 (2004).
39. Tattevin P, Bruneel F, Lellouche F et al. Successful treatment of brain aspergillosis with voriconazole. Clin. Microbiol. Infect. 10(10), 928-931 (2004).
40. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98, 292-299 (2003).
41. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45(1), 327-330 (2001).
42. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41(11), 2326-2332 (1997).
43. Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. 41(2), 331-336 (1997).
44. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20(4), 121-136 (2003).
45. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin. Microbiol. Infect. 10(10), 925-928 (2004).
46. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909-917 (2002).
47. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematological patients. Haematologica 89, 207-214 (2004).
48. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk. Lymphoma 45(7), 1351-1360 (2004).
49. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47(11), 3647-3650 (2003).
50. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58(6), 612-624 (2004).
51. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46(5), 1581-1582 (2002).
52. Handzel O, Landau Z, Halperin D. Liposomal amphotericin B treatment for rhinocerebral mucormycosis: how much is enough? Rhinology 41(3), 184-186 (2003).
53. Barron MA, Lay M, Madinger NE. Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation. J. Clin. Microbiol. 43(4), 2012-2014 (2005)
54. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 46, 1032-1037 (2002).
55. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51, 45-52 (2003).
56. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350, 950-952 (2004).
57. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39, 743-746 (2004).
58. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191, 350-360 (2005).
59. Greenberg RN, Anstead G, Herbrecht R et al. Posaconazole (POS) experience in the treatment of zygomycosis. 42 Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, September 14-17 (2003).
60. Guo LS. Amphotericin B colloidal dispersion: an improved antifungal therapy. Adv. Drug Deliv. Rev. 47(2-3), 149-163 (2001).
61. Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect. Med. 20, 201-206 (2003).
62. Walsh TH, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (Ambisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45, 3487-3496 (2001).
63. Nesky MA, McDougal EC, Peacock JE Jr. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis. 31(3), 673-677 (2000).
64. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45, 2151-2153 (2001).
65. Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int. J. Antimicrob. Agents 18, 167-172 (2001).
66. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis. 1534(12), 1648-1650 (2002)
67. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin. Infect. Dis. 38(2), 206-216 (2004).
68. Nucci M, Anaissie EJ, Queiroz-Telles F et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98(2), 315-319 (2003).
69. Agamanolis DP, Kalwinsky DK, Krill CE Jr, Dasu S, Halasa B, Galloway PG. Fusarium meningoencephalitis in a child with acute leukemia. Neuropediatrics 22(2), 110-112 (1991).
70. Voice RA, Bradley SF, Sangeorzan JA, Kauffman CA. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin. Infect. Dis. 19(1), 60-66 (1994).
71. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28, 1071-1079 (1999).
72. Lai PH, Lin SM, Pan HB, Yang CF. Disseminated miliary cerebral candidiasis. Am. J. Neuroradiol. 18(7), 1303-1306 (1997).
73. Chen TL, Tsai CA, Fung CP, Lin MY, Yu KW, Liu CY. Clinical significance of Candida species isolated from cerebrospinal fluid. J. Microbiol. Immunol. Infect. 35(4), 249-254 (2002).
74. Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn. Microbiol. Infect. Dis. 37(3), 169-179 (2000).
75. Verduyn Lunel FM, Voss A, Kuijper EJ et al. Detection of the Candida antigen mannan in cerebrospinal fluid specimens from patients suspected of having Candida meningitis. J. Clin. Microbiol. 42(2), 867-870 (2004).
76. Ralph ED, Hussain Z. Chronic meningitis caused by Candida albicans in a liver transplant recipient: usefulness of the polymerase chain reaction for diagnosis and for monitoring treatment. Clin. Infect. Dis. 23(1), 191-192 (1996).
77. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38(2), 161-189 (2004).
78. Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin. Respir. Infect. 16(4), 263-269 (2001).
79. Liu KH, Wu CJ, Chou CH et al. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J. Clin. Microbiol. 42(12), 5950-5953 (2004).
80. Odio CM, Araya R, Pinto LE et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23(12), 1093-1097 (2004).
81. Deresinski SC, Stevens DA. Caspofungin. Clin. Infect. Dis. 36, 1445-1457 (2003).
82. Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J. Antimicrob. Chemother. 51, 1427-1429 (2003)
83. Pappas PG, Perfect JR, Cloud GA et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33, 690-699 (2004).
84. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin. Infect. Dis. 4, 98-107 (2002).
85. Vigouroux S, Morin O, Milpied N, Mahe B, Rapp MJ, Harousseau JL. Cryptococcus neoformans infection in hematologic malignancies. Rev. Med. Interne. 21, 955-960 (2000).
86. Pagano L, Fianchi L, Caramatti C et al. for GIMEMA Infection Program. Cryptococcosis in patients with hematological malignancies, report by GIMEMA-Infection. Haematologica 89, 852-856 (2004).
87. Kontoyiannis DF, Peitsch WK, Reddy BT et al. Cryptococcosis in patients with cancer. Clin. Infect. Dis. 1(32), E145-E150 (2001).
88. Lortholary O, Charlemagne A, Bastides F et al. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. J. Antimicrob. Chemother. 54(2), 456-464 (2004).
89. Cheng YC, Ling JF, Chang FC et al. Radiological manifestations of cryptococcal infection in central nervous system. J. Chin. Med. Assoc. 66(1), 19-26 (2003).
90. Gottfredsson M, Perfect JR. Fungal meningitis. Semin. Neurol. 20(3), 307-322 (2000).
91. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 710-718 (2000).
92. Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. 19(3), 126-131 (1979).
93. Dismukes WE, Cloud G, Gallis HA et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N. Engl. J. Med. 317(6), 334-341 (1987).
94. White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J. Infect. Dis. 165(5), 960-963 (1992).
95. Polsky B, Depman MR, Gold JW, Galicich JH, Armstrong D. Intraventricular therapy of cryptococcal meningitis via a subcutaneous reservoir. Am. J. Med. 81(1), 24-28 (1986).
96. Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am. J. Med. 91, 267-272 (1991)
97. Girmenia C, Pagano L, Martino B et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J. Clin. Microbiol. 43(4), 1818-1828 (2005).
98. Ogata K, Tanabe Y, Iwakiri K et al. Two cases of disseminated Trichosporon beigelii infection treated with combination antifungal therapy. Cancer 65, 2793-2795 (1990).
99. Amft N, Miadonna A, Viviani MA, Tedeschi A. Disseminated Geotrichum capitatum infection with predominant liver involvement in a patient with non-Hodgkins lymphoma. Haematologica 81, 352-355 (1996).
100. Girmenia C, Micozzi A, Venditti M et al. Fluconazole treatment of Blastoschizomyces capitatus meningitis in an allogeneic bone marrow recipient. Eur. J. Clin. Microbiol. Infect. Dis. 10, 752-756 (1991).
101. Walsh TJ, Melcher GP, Rinaldi MG et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. 28, 1616-1622 (1990).
102. Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine 65, 268-279 (1986).
103. Walsh TJ. Trichosporonosis. Infect. Dis. Clin. North Am. 3, 43-52 (1989).
104. Hoy J, Hsu KC, Rolston K, Hopfer RL, Luna M, Bodey GP. Trichosporon beigelii infection: a review. Rev. Infect. Dis. 8, 959-967 (1986).
105. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(Suppl. 1), 48-66 (2004).
106. Anaissie EJ, Hachem R, Karyotakis NC et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob. Agents Chemother. 38, 2541-2544 (1994).
107. Falk R, Wolf DG, Shapiro M, Polacheck I. Multi-drug resistant Trichosporon asahii isolates are susceptible to voriconazole. J. Clin. Microbiol. 41, 911 (2003).